AzurRx BioPharma, Inc (AZRX)

Etorro trading 970x250
AzurRx BioPharma, Inc (AZRX) Logo

About AzurRx BioPharma, Inc

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company’s lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients). It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida with scientific operations in Langlade, France and clinical operations in Hayward, California. Address: 1615 South Congress Avenue, Delray Beach, FL, United States, 33445

AzurRx BioPharma, Inc News and around…

Latest news about AzurRx BioPharma, Inc (AZRX) common stock and company :

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis
28 Sep, 2021 Yahoo! Finance

Preliminary data from prior Phase 1a/2a trial indicated safety of topical formulation of FW-UP and suggested possible favorable efficacy First Proof of Principle for Treatment of Inflammatory Bowel Disease with Niclosamide BOCA RATON, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma”, “First Wave”, or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastroin

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
21 Sep, 2021 FinancialContent

Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

3 Penny Stocks That Top Investors Buying Right Now
15 Sep, 2021 FinancialContent
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

46 Biggest Movers From Yesterday
15 Sep, 2021 FinancialContent

Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special ...

Why AzurRx BioPharma's Stock Is Trading Higher Today
14 Sep, 2021 FinancialContent

AzurRx BioPharma(NASDAQ:AZRX)shares are trading higher after the company announced it will acquire First Wave Bio. AzurRx ...

36 Stocks Moving In Tuesday's Mid-Day Session
14 Sep, 2021 FinancialContent

Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 ...

AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
14 Sep, 2021 Yahoo! Finance

AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.

Mid-Morning Market Update: Markets Mostly Lower; US Annual Inflation Rate Slows to 5.3% in August
14 Sep, 2021 FinancialContent

Following the market opening Tuesday, the Dow traded down 0.26% to 34,778.27 while the NASDAQ rose 0.01% to 15,106.84. The S&P also ...

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
14 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
14 Sep, 2021 FinancialContent
AzurRx BioPharma To Acquire First Wave Bio In Transformative $229 Million Deal; Significantly Expands GI and IBD Treatment Pipeline (NASDAQ: AZRX)
14 Sep, 2021 FinancialContent
72 Biggest Movers From Yesterday
14 Sep, 2021 FinancialContent

Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from ...

AzurRx BioPharma Announces Reverse Merger With First Wave Bio
13 Sep, 2021 FinancialContent

AzurRx BioPharma Inc(NASDAQ: AZRX) hasagreed to acquireFirst Wave Bio Incin a stock and cash transaction ...

AzurRx BioPharma To Acquire First Wave Bio For $229M
13 Sep, 2021 Yahoo! Finance

AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments. First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD). In conjunction with the acquisition, AzurRx will change its name to First Wave BioPharma and trade on NASDAQ under the new ticker symbol, FWBI, effective by Septemb

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
13 Sep, 2021 FinancialContent
AzurRx BioPharma Announces Reverse Stock Split
10 Sep, 2021 FinancialContent

Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021

AzurRx BioPharma Shares Surge 14% Since August As RESERVOIR, PASSPORT, and MS1819 Trials Reach Critical Milestones (NASDAQ: AZRX)
10 Sep, 2021 FinancialContent
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
10 Sep, 2021 FinancialContent

Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-1
09 Sep, 2021 FinancialContent
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
09 Sep, 2021 Yahoo! Finance

Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned Part 2 of RESERVOIR Trial to Enroll Up to 150 Patients to Evaluate Efficacy of FW-1022 and Extend Safety Observations BOCA RATON, Fla., Sept. 09, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that an independent dat

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis
08 Sep, 2021 FinancialContent

Proposed Phase 1b/2a clinical trial designed to determine safety and potential efficacy of oral and topical FW-420

AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 FinancialContent
AzurRx BioPharma Phase 2 MS1819 Data Too Good to Ignore; Data Supports Front Line Position To Treat EPI In Patients With Cystic Fibrosis (NASDAQ: AZRX)
26 Aug, 2021 FinancialContent
3 Penny Stocks That Top Investors Are Buying Right Now
25 Aug, 2021 FinancialContent
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
24 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We're getting ready for another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

AzurRx BioPharma, Inc (AZRX) is a NASDAQ Common Stock listed in , ,

970x250